Court Decisions Negative 6

FTC sues Hims & Hers over health data sharing; stock drops 8.7%

The FTC’s civil suit against Hims & Hers alleges deceptive privacy and billing practices. Legal teams now face renewed scrutiny over digital health marketing compliance and the use of tracking pixels under the FTC Act.

· 4 min read · Verified by 2 sources ·

Beat this week

Last 7 days · Court Decisions

23 stories
5 avg impact
4% positive
0% negative
vs prior 7 days -10 -10 stories vs prior 7 days

Impact 5.0/10 (-0.3 vs prior). Counts are stories in our record, not a market forecast.

Open the change report

Coverage balance Balanced directional read. Positive and negative coverage are within 4 percentage points.

  • 4% positive
  • 96% neutral

This story sits in Court Decisions — the counts compare this beat's last 7 days with the previous 7 in our verified record, not a market forecast.

Figures are computed live from our source-verified story record (as of ) The volume change compares this window with the prior 7 days in the same record. — see our methodology for how impact and sentiment are derived.

Legal briefing

Key takeaways

6 impact
Negativesentiment
2sources
4min read
  1. The FTC’s civil suit against Hims & Hers alleges deceptive privacy and billing practices.
  2. Legal teams now face renewed scrutiny over digital health marketing compliance and the use of tracking pixels under the FTC Act.
Drawn from
  • my9nj.com
  • fox4news.com

In this briefing

Mentioned

Key Intelligence

Key Facts

  1. 1The FTC filed a civil lawsuit against Hims & Hers in late July 2026 for allegedly sharing users’ health information with Meta and Snap via tracking pixels, despite privacy promises.
  2. 2The complaint also accuses Hims & Hers of deceptive billing and cancellation practices that made it difficult for consumers to end subscriptions.
  3. 3Hims & Hers publicly denied the allegations as “baseless” and “an effort to generate headlines at our expense” in a post on X.
  4. 4The suit alleges that pixel data transmitted included information about users’ health conditions, treatment interests, and medication purchases.
  5. 5HIMS shares fell 8.7% on the day the lawsuit was reported, reflecting immediate investor concern over potential fines and reputational damage.
  6. 6Previous FTC actions against GoodRx and BetterHelp for similar pixel-based health-data sharing resulted in settlements of $1.5M and $7.8M, respectively.

The FTC will not hesitate to act on behalf of consumers deprived of their ability to choose which products they want and whether to keep their most sensitive health information private.

Christopher Mufarrige Director, FTC Bureau of Consumer Protection

Statement on the filing of the lawsuit

HIMSHims & Hers Health, Inc.
$12.50-1.20 (-8.70%) as of Aug 1, 2026

Analysis

For legal and compliance professionals, the FTC’s lawsuit against Hims & Hers signals an aggressive new front in regulating digital health privacy. The case underscores the risks of tracking pixels and deceptive cancellation practices under Section 5 of the FTC Act, with potential penalties reaching millions.

The Federal Trade Commission has filed a civil lawsuit against telehealth company Hims & Hers, alleging the company systematically shared sensitive health information with advertising giants Meta and Snap despite explicit privacy promises to users. The suit, filed in federal court in late July 2026, accuses the San Francisco-based startup—known for connecting patients with providers for conditions ranging from sexual health to mental wellness—of embedding tracking pixels that transmitted data about users’ health-related browsing behavior, product selections, and even purchase histories to social media platforms. FTC Director of the Bureau of Consumer Protection Christopher Mufarrige stated the agency “will not hesitate to act on behalf of consumers deprived of their ability to choose... whether to keep their most sensitive health information private,” signaling a muscular new phase in digital health privacy enforcement.

This approach mirrors recent FTC actions against GoodRx ($1.5 million civil penalty in 2023 for sharing health data with Meta and Google) and BetterHelp ($7.8 million settlement in 2023 for similar pixel-based data leaks).

The FTC’s complaint also targets Hims & Hers’ billing and cancellation practices, alleging the company made it unreasonably difficult for consumers to cancel subscriptions and charged them without proper authorization. These allegations fall squarely under Section 5 of the FTC Act, which prohibits unfair or deceptive acts. Because Hims & Hers is not a HIPAA-covered entity (the platform acts as a technology intermediary rather than a healthcare provider billing insurance), the FTC cannot directly enforce HIPAA; instead, it uses its broad consumer protection mandate to punish deceptive privacy representations. This approach mirrors recent FTC actions against GoodRx ($1.5 million civil penalty in 2023 for sharing health data with Meta and Google) and BetterHelp ($7.8 million settlement in 2023 for similar pixel-based data leaks). The current suit suggests the FTC is prepared to escalate penalties and pursue injunctive relief that could reshape data practices across the entire telehealth sector.

What to Watch

The implications extend well beyond a single company. Health-tracking pixels—small code snippets that fire when a user visits a website—are ubiquitous in digital marketing. When a Hims & Hers user browsed for erectile dysfunction treatments or selected an anxiety medication, those pixel events told Meta and Snap that a specific device ID was interested in those health conditions, enabling hyper-targeted advertising. Privacy researchers have long warned that such data can be combined with other signals to re-identify individuals, and the FTC now treats these practices as inherently deceptive when a company’s privacy policy says it does not share health information. For investors, the immediate market reaction was stark: HIMS shares tumbled 8.7% on the news, wiping out a significant portion of the company’s market value and underscoring the financial materiality of privacy compliance failures.

The company’s aggressive denial—calling the FTC’s move “an effort to generate headlines at our expense”—may resonate with an industry that often views such enforcement as regulation by ambush, but legal experts note that the FTC rarely files a federal lawsuit without what it believes is strong evidence. Penalties could climb into the tens of millions if the court finds a pattern of violations, especially given the large user base and the sensitivity of the data. Moreover, the case could spur class-action litigation from consumers, further pressuring the company. Forward-looking, this lawsuit will likely accelerate adoption of server-side tracking and consent management platforms that limit third-party data leakage, while also pushing telehealth firms to conduct rigorous audits of their marketing technology stacks. The FTC’s action reminds every digital health company that privacy promises are not marketing copy—they are legally binding commitments that, when broken, can draw the full weight of federal enforcement.

Timeline

Timeline

  1. FTC files civil lawsuit against Hims & Hers

Source cluster

Primary reporting

2articles

Cite This Page

"FTC sues Hims & Hers over health data sharing; stock drops 8.7%." Legal & RegTech Intelligence Brief, August 1, 2026. https://getlegalbrief.com/story/hims-and-hers-ftc-lawsuit-health-data-sharing

How we covered this story

Every story in our legal coverage is assembled from multiple primary sources, cross-referenced for factual consistency, and scored along three independent dimensions: sentiment, operational impact, and source-cluster confidence. Single-source rumors and unverifiable claims do not pass our editorial gate. When a story shows "Verified by N sources" with N≥2, the development is independently corroborated; when N=1, we mark it explicitly so readers can weigh the signal accordingly.

Impact scoring uses a 1-10 scale weighted toward regulatory, financial, and operational consequence rather than coverage volume. A topic that runs in every outlet but moves no real decisions ranks lower than a niche regulatory filing that reshapes how operators in the legal space have to behave. Read our full methodology for the scoring rubric, our glossary for term definitions, and our trends index for the longitudinal view across the beat.

Sources are only linked to a story once they clear our classification pipeline at a minimum 35 percent relevance threshold. According to that methodology, reviewed July 2026, this follows multi-source corroboration standards recommended by journalism research bodies such as the Reuters Institute for the Study of Journalism.

See something wrong in this story — a wrong fact, a broken source link, a misattributed entity? Report a data issue.